These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 35796870)

  • 1. Blood-based Aβ42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention.
    Botella Lucena P; Vanherle S; Lodder C; Gutiérrez de Ravé M; Stancu IC; Lambrichts I; Vangheluwe R; Bruffaerts R; Dewachter I
    Acta Neuropathol; 2022 Sep; 144(3):489-508. PubMed ID: 35796870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App
    Andersson E; Schultz N; Saito T; Saido TC; Blennow K; Gouras GK; Zetterberg H; Hansson O
    Alzheimers Res Ther; 2023 Mar; 15(1):64. PubMed ID: 36964585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
    Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
    J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
    Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
    Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
    J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's Aβ amyloidosis.
    Jiang R; Smailovic U; Haytural H; Tijms BM; Li H; Haret RM; Shevchenko G; Chen G; Abelein A; Gobom J; Frykman S; Sekiguchi M; Fujioka R; Watamura N; Sasaguri H; Nyström S; Hammarström P; Saido TC; Jelic V; Syvänen S; Zetterberg H; Winblad B; Bergquist J; Visser PJ; Nilsson P
    Acta Neuropathol Commun; 2022 Jul; 10(1):96. PubMed ID: 35787306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
    Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O
    Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease.
    de Leon MJ; Pirraglia E; Osorio RS; Glodzik L; Saint-Louis L; Kim HJ; Fortea J; Fossati S; Laska E; Siegel C; Butler T; Li Y; Rusinek H; Zetterberg H; Blennow K; ;
    PLoS One; 2018; 13(2):e0191240. PubMed ID: 29415068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
    Pascual-Lucas M; Allué JA; Sarasa L; Fandos N; Castillo S; Terencio J; Sarasa M; Tartari JP; Sanabria Á; Tárraga L; Ruíz A; Marquié M; Seo SW; Jang H; Boada M;
    Alzheimers Res Ther; 2023 Jan; 15(1):2. PubMed ID: 36604729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Co-oligomers of Aβ42 and Human Islet Amyloid Polypeptide Exacerbate Neurotoxicity and Alzheimer-like Pathology at Cellular Level.
    Deng J; Liu B; Tao Q; Luo Y; Zhu Y; Huang X; Yue F
    Neuroscience; 2024 May; 547():37-55. PubMed ID: 38604526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease related biomarkers in bipolar disorder - A longitudinal one-year case-control study.
    Knorr U; Simonsen AH; Jensen CS; Zetterberg H; Blennow K; Akhøj M; Forman J; Hasselbalch SG; Kessing LV
    J Affect Disord; 2022 Jan; 297():623-633. PubMed ID: 34728295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease.
    Tzen KY; Yang SY; Chen TF; Cheng TW; Horng HE; Wen HP; Huang YY; Shiue CY; Chiu MJ
    ACS Chem Neurosci; 2014 Sep; 5(9):830-6. PubMed ID: 25054847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.